We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

The future: from the bench to the patient

    Kris De Boeck

    Kris De Boeck is Professor of Pediatrics at the University of Leuven (Belgium) and Head of the Pediatric Service of Pulmonology and Infectious Diseases at the University Hospital Gasthuisberg (Leuven, Belgium). She is a clinician and clinical researcher and leads the Reference Center for Cystic Fibrosis in Leuven. Her special interest goes to diagnostic issues and outcome parameters for use in clinical trials. She was the first Director of European Cystic Fibrosis Society–Clinical Trial Network from 2008 till 2012. At present, she is Vice-President of the European Cystic Fibrosis Society.

    Search for more papers by this author

    Published Online:27 Jun 2013https://doi.org/10.2217/ebo.12.526
    Abstract:

    Great strides have been made in the past 20 years, but we must not lose momentum until we have reached our ultimate goal, which is finding an effective treatment for every patient with cystic fibrosis, whatever his or her CFTR mutations.

    References

    • 1  Jacquot J , Tabary O , Le Rouzic P et al. Airway epithelial cell inflammatory signalling in cystic fibrosis . Int. J. Biochem. Cell Biol. 40 (9) , 1703 – 1715 (2008) .
      Medline CASGoogle Scholar
    • 2  Zhou Z , Duerr J , Johannesson B et al. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease . J. Cyst. Fibros. 10 (Suppl. 2) , S172 – S182 (2011) .
      Medline CASGoogle Scholar
    • 3  Chen JH , Stoltz DA , Karp PH et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia . Cell 143 (6) , 911 – 923 (2010) .
      Medline CASGoogle Scholar
    • 4  Yang YD , Cho H , Koo JY et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance . Nature 455 (7217) , 1210 – 1215 (2008) .
      Medline CASGoogle Scholar
    • 5  Ramsey BW , Davies J , McElvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation . N. Engl. J. Med. 365 (18) , 1663 – 1672 (2011) .
      Medline CASGoogle Scholar
    • 6  Yu H , Burton B , Huang CJ et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations . J. Cyst. Fibros. 11 (3) , 237 – 245 (2012) .
      Medline CASGoogle Scholar
    • 7  Lukacs GL , Verkman AS . CFTR: folding, misfolding and correcting the ΔF508 conformational defect . Trends Mol. Med. 18 (2) , 81 – 91 (2012) .
      Medline CASGoogle Scholar
    • 8  Linde L , Kerem B . Nonsense-mediated mRNA decay and cystic fibrosis . Methods Mol. Biol. 741 , 137 – 154 (2011) .
      Medline CASGoogle Scholar
    • 9  Stoltz DA , Meyerholz DK , Pezzulo AA et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth . Sci. Transl. Med. 2 (29) , 29 – 31 (2010) .
      Google Scholar
    • 10  Gillanders L , Elborn JS , Gilpin DF et al. The airway microbiome in cystic fibrosis: challenges for therapy . Therapy 8 (6) , 645 – 660 (2011) .
      Google Scholar
    • 11  Zhao J , Schloss PD , Kalikin LM et al. Decade-long bacterial community dynamics in cystic fibrosis airways . Proc. Natl Acad. Sci. USA 109 (15) , 5809 – 5814 (2012) .
      Medline CASGoogle Scholar
    • 12  Meyerholz DK , Stoltz DA , Namati E et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children . Am. J. Respir. Crit. Care Med. 182 (10) , 1251 – 1261 (2010) .
      MedlineGoogle Scholar
    • 13  Rogan MP , Reznikov LR , Pezzulo AA et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth . Proc. Natl Acad. Sci. USA 107 (47) , 20571 – 20575 (2010) .
      Medline CASGoogle Scholar
    • 14  Stick SM , Brennan S , Murray C et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening . J. Pediatr. 155 (5) , 623 – 628.e1 (2009) .
      MedlineGoogle Scholar
    • 15  Belessis Y , Dixon B , Hawkins G et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index . Am. J. Respir. Crit. Care Med. 185 (8) , 862 – 873 (2012) .
      MedlineGoogle Scholar
    • 16  Smyth AR , Barbato A , Beydon N et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities . Eur. Respir. J. 35 (2) , 247 – 265 (2010) .
      Medline CASGoogle Scholar
    • 17  Ramsey BW , Banks-Schlegel S , Accurso FJ et al. Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report . Am. J. Respir. Crit. Care Med. 185 (8) , 887 – 892 (2012) .
      MedlineGoogle Scholar
    • 18  De Boeck K , Kent L , Davies J et al. CFTR biomarkers: time for promotion to surrogate endpoint? . Eur. Respir. J. 41 (1) , 203 – 216 (2013) .
      Medline CASGoogle Scholar
    • 19  Dolmage TE , Hill K , Evans RA et al. Has my patient responded? Interpreting clinical measurements such as the 6-minute-walk test . Am. J. Respir. Crit. Care Med. 184 (6) , 642 – 646 (2011) .
      MedlineGoogle Scholar